Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mária Zvaríková"'
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 35(3)
Meigs syndrome is defined by the presence of a benign ovarian tumor, ascites, and pleural effusion (predominantly on the right side). A characteristic sign of Meigs syndrome is the complete disappearance of exudate after surgical resection of the ova
Autor:
Iveta Selingerová, Tomas Kazda, Ivana Kolouskova, Katarína Petráková, Miloš Holánek, Oldrich Coufal, Ondrej Bilek, Radka Obermannova, Lenka Foretova, Pavel Fabian, Marek Svoboda, Alexandr Poprach, Mária Zvaríková
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Cancers, Vol 13, Iss 1586, p 1586 (2021)
Volume 13
Issue 7
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a m
Autor:
Stanislav Špelda, Jan Podhorec, Simona Bořilová, Mária Zvaríková, L. Kristková, Ondřej Bílek, O. Horký, Miloš Holánek, Jitka Berkovcová, Lucia Bohovicova, L Zdražilová Dubská, Helena Čoupková, Tomáš Kazda
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 32(Supplementum 3)
Background Epidermal growth factor receptor (EGFR) mutations play an important role in the pathogenesis of non-small cell lung cancer. Because these alterations are so-called targetable mutations, their identification is important in daily clinical p
Autor:
Rudolf Nenutil, Tomáš Kazda, Miloš Holánek, Iveta Selingerová, Katarína Petráková, Markéta Palácová, Rostislav Vyzula, Ondřej Bílek, Marta Krásenská, Mária Zvaríková
Publikováno v:
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 32(Supplementum2)
Background Mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing breast cancer. Tumors arising from this mutation are expected to be more sensitive to platinum-based drugs. The role of platinum-based drugs in systemic n
Publikováno v:
Klinicka Onkologie. 30:294-298
Here, we present the case of a 50-year-old woman diagnosed with stage I hormone-dependent breast cancer. The patient underwent partial mastectomy followed by adjuvant radiotherapy and hormone treatment with tamoxifen. Three years later, she presented
Autor:
Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda
Publikováno v:
Diagnostics, Vol 12, Iss 7, p 1740 (2022)
A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecut
Externí odkaz:
https://doaj.org/article/683bdd4ed2e2407987165083b0d972a6
Autor:
Milos Holanek, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal, Katarina Petrakova, Marek Svoboda, Alexandr Poprach
Publikováno v:
Cancers, Vol 13, Iss 7, p 1586 (2021)
Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a m
Externí odkaz:
https://doaj.org/article/705e0daa58fc46d2bc23b87a1e6fe6d9